Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)

Market Cap	816.37M
Revenue (ttm)	-1.00K
Net Income (ttm)	-125.83M
Shares Out	13.47M
EPS (ttm)	-9.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,696
Average Volume	22,187
Open	61.80
Previous Close	61.70
Day's Range	60.50 - 63.60
52-Week Range	21.70 - 135.00
Beta	0.46
RSI	63.49
Earnings Date	May 7, 2025

About STO:IBT.B

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IBT.B

Financial Performance

In 2024, STO:IBT.B's revenue was 4,000, a decrease of -94.81% compared to the previous year's 77,000. Losses were -136.91 million, 11.2% more than in 2023.